Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Oragenics (NYSE American: OGEN), a biotech company focused on intranasal therapeutics for brain-related conditions, announces its participation in two major industry events in June 2025. Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention in Boston (June 16-19), where he will discuss ONP-002, the company's lead intranasal neurosteroid candidate for treating concussion. Additionally, Oragenics will attend the 42nd Annual National Neurotrauma Society Symposium in Philadelphia (June 15-18), co-hosted by the National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care. These events provide platforms for Oragenics to showcase its development pipeline and engage with industry leaders in neuroscience, neurology, biotech, and pharma.
Oragenics (NYSE American: OGEN), un'azienda biotecnologica specializzata in terapie intranasali per condizioni cerebrali, annuncia la sua partecipazione a due importanti eventi del settore a giugno 2025. Greg Gironda, Responsabile dello Sviluppo Commerciale, presenterà al BIO International Convention 2025 a Boston (16-19 giugno), dove parlerà di ONP-002, il principale candidato neurosteroide intranasale dell'azienda per il trattamento della commozione cerebrale. Inoltre, Oragenics parteciperà al 42° Simposio Annuale della National Neurotrauma Society a Filadelfia (15-18 giugno), co-organizzato dalla National Neurotrauma Society e dalla Sezione Congiunta AANS/CNS su Neurotrauma e Cure Critiche. Questi eventi offrono a Oragenics l'opportunità di mostrare il proprio pipeline di sviluppo e di confrontarsi con leader del settore nelle neuroscienze, neurologia, biotecnologia e farmaceutica.
Oragenics (NYSE American: OGEN), una empresa biotecnológica centrada en terapias intranasales para condiciones cerebrales, anuncia su participación en dos importantes eventos de la industria en junio de 2025. Greg Gironda, Jefe de Desarrollo Comercial, presentará en la Convención Internacional BIO 2025 en Boston (16-19 de junio), donde hablará sobre ONP-002, el principal candidato neuroesteroide intranasal de la compañía para el tratamiento de conmociones cerebrales. Además, Oragenics asistirá al 42º Simposio Anual de la National Neurotrauma Society en Filadelfia (15-18 de junio), coorganizado por la National Neurotrauma Society y la Sección Conjunta AANS/CNS sobre Neurotrauma y Cuidados Críticos. Estos eventos ofrecen a Oragenics plataformas para mostrar su pipeline de desarrollo y relacionarse con líderes de la industria en neurociencia, neurología, biotecnología y farmacéutica.
Oragenics(NYSE American: OGEN)는 뇌 관련 질환에 대한 비강 내 치료제에 주력하는 바이오테크 기업으로, 2025년 6월 두 개의 주요 산업 행사에 참여한다고 발표했습니다. 사업개발 책임자인 Greg Gironda는 2025년 6월 16일부터 19일까지 보스턴에서 열리는 BIO 국제 컨벤션에서 회사의 주요 비강 내 신경스테로이드 후보물질인 ONP-002를 소개하며 뇌진탕 치료에 대해 발표할 예정입니다. 또한 Oragenics는 6월 15일부터 18일까지 필라델피아에서 개최되는 제42회 연례 National Neurotrauma Society 심포지엄에도 참석하며, 이 행사는 National Neurotrauma Society와 AANS/CNS 공동 신경외상 및 중환자 관리 분과가 공동 주최합니다. 이 행사들은 Oragenics가 개발 파이프라인을 선보이고 신경과학, 신경학, 바이오테크, 제약 분야의 업계 리더들과 교류할 수 있는 기회를 제공합니다.
Oragenics (NYSE American : OGEN), une entreprise biotechnologique spécialisée dans les thérapies intranasales pour les affections cérébrales, annonce sa participation à deux événements majeurs de l'industrie en juin 2025. Greg Gironda, responsable du développement commercial, présentera lors de la Convention Internationale BIO 2025 à Boston (du 16 au 19 juin), où il abordera ONP-002, le principal candidat neurostéroïde intranasal de la société pour le traitement des commotions cérébrales. Par ailleurs, Oragenics assistera au 42e Symposium annuel de la National Neurotrauma Society à Philadelphie (du 15 au 18 juin), co-organisé par la National Neurotrauma Society et la section conjointe AANS/CNS sur le neurotraumatisme et les soins intensifs. Ces événements offrent à Oragenics des plateformes pour présenter son pipeline de développement et échanger avec les leaders de l'industrie en neurosciences, neurologie, biotechnologie et pharmacie.
Oragenics (NYSE American: OGEN), ein Biotechnologieunternehmen, das sich auf intranasale Therapien für gehirnbezogene Erkrankungen spezialisiert hat, kündigt seine Teilnahme an zwei wichtigen Branchenevents im Juni 2025 an. Greg Gironda, Leiter Geschäftsentwicklung, wird auf der BIO International Convention 2025 in Boston (16.-19. Juni) präsentieren und dabei ONP-002 vorstellen, den führenden intranasalen Neurosteroid-Kandidaten des Unternehmens zur Behandlung von Gehirnerschütterungen. Zudem wird Oragenics am 42. Jahressymposium der National Neurotrauma Society in Philadelphia (15.-18. Juni) teilnehmen, das gemeinsam von der National Neurotrauma Society und der AANS/CNS Joint Section on Neurotrauma & Critical Care veranstaltet wird. Diese Veranstaltungen bieten Oragenics die Möglichkeit, seine Entwicklungspipeline zu präsentieren und sich mit Branchenführern aus den Bereichen Neurowissenschaften, Neurologie, Biotechnologie und Pharma auszutauschen.
Positive
- None.
Negative
- None.
SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania.
These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.
2025 BIO International Convention
- Dates: June 16–19, 2025
- Location: Boston Convention & Exhibition Center, Boston, MA
- Presentation Date & Time: June 19, 2025, from 11:30 AM – 11:45 AM ET
- Registration: https://www.bio.org/events/bio-international-convention/registration
42nd Annual National Neurotrauma Society (NNS) Symposium
- Dates: June 15–18, 2025
- Location: Philadelphia Marriott Downtown, Philadelphia, PA
- Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care
About Oragenics, Inc.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company’s intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit www.oragenics.com.
Investor Contact:
Rich Cockrell
CG Capital
866.889.1972
ogen@cg.capital
FAQ
When and where will Oragenics (OGEN) present at the 2025 BIO International Convention?
Oragenics will present on June 19, 2025, from 11:30 AM to 11:45 AM ET at the Boston Convention & Exhibition Center in Boston, MA.
What is Oragenics' (OGEN) lead drug candidate ONP-002?
ONP-002 is an intranasal neurosteroid being developed for the treatment of concussion (mild traumatic brain injury).
Which two major industry events will Oragenics (OGEN) attend in June 2025?
Oragenics will attend the 2025 BIO International Convention in Boston (June 16-19) and the 42nd Annual National Neurotrauma Society Symposium in Philadelphia (June 15-18).
Who will represent Oragenics (OGEN) at the 2025 BIO International Convention?
Greg Gironda, Head of Business Development at Oragenics, will present at the convention.
Oragenics
NYSE:OGEN
OGEN Rankings
OGEN Latest News
OGEN Stock Data
2.65M
681.37k
13.3%
1.14%
2.86%
Biotechnology
Pharmaceutical Preparations
United States
SARASOTA